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Ongoing production of spermatozoa from spermatogonial stem cells requires a balance between self-renewal and differentiation to maintain full fertility. Several studies have identified key markers and molecular cues that are specific to the spermatogonial stem cell fate choice in a healthy testis [1-3; reviewed in 4] . The endocrine and paracrine cues that govern spermatogenic progression are understood to contribute to the balance between these outcomes, but the molecular details underpinning this balance are not yet apparent. The study in the current issue by Zhou and colleagues [5] adds to our expanding knowledge of the mechanisms by which cell fate choices occur in the context of spermatogenic recovery in the adult testis.
Each testicular cell type is simultaneously exposed to a dynamic set of signaling inputs comprised of both endocrine and paracrine factors. Estrogen acts both on the interstitial compartment and directly on cells within the seminiferous epithelium to influence spermatogenesis [6] [7] [8] . Estrogen receptor knockout studies have clearly revealed the importance of estrogen signaling for fluid resorption within cells of the efferent ducts and epididymal epithelium (e.g., [9, 10] ); however the roles of estrogens in spermatogenesis are still unresolved. They have been ascribed contradictory functions depending on the model or physiological circumstances (e.g., [11] ). Knowledge of the underlying molecular players has begun to emerge only recently, and the challenge of discerning estrogen-specific effects that are clearly distinct from those modulated by other hormones remains a significant technical challenge.
There is limited but growing knowledge of where and how estrogen signaling contributes to the earliest germline fate decision. In the context of the first wave of spermatogenesis, as the gonocyte transitions either into an SSC or into a differentiating spermatogonium, the outcome is affected by the specific hormonal milieu. Kula and colleagues concluded that estrogens can stimulate male germ cell maturation by acting in synergy with FSH, or by direct action on germ cells [12] , thus providing an important foundation for the present study. In the cryptorchid mouse, where only stem cells are found, 17b-estradiol administration promotes spermatogonial proliferation [13] . In ERb knockout mice, there is an elevated number of gonocytes in newborn mice; this is a result of decreased apoptosis [14] . However, exposure of newborn rats to 17b-estradiol reduced gonocyte migration to the basement membrane and reduced gonocyte proliferation and apoptosis [15] . Estrogens appear to play a role in governing PDGFmediated signaling outcomes in rat gonocytes [8, 16] and in influencing spermatogonial proliferation in newborns [17] , but the mechanism remains elusive. To date, these are the limited pathways identified by which estrogen influences events at the onset of spermatogenesis in normal testis development.
The ongoing program of the Meistrich lab has focussed on adult stem cell maintenance and recovery after radiation. Reflecting the objective of addressing the clinical need to aid spermatogenic recovery in adults, an adult rat model in which radiation results in depletion of all differentiating germ cells has been developed. Spermatogenic recovery after irradiation is minimal and slow due to elevated intratesticular testosterone; administration of gonadotropin releasing hormone (GnRH) modulators suppresses intratesticular testosterone (ITT) and stimulates the emergence of differentiating germ cells; estrogen administration enhances this recovery [18] . The study by Zhou and colleagues [5] makes significant progress towards a mechanistic understanding of how estrogen interacts with other pathways in the adult testis to influence normal and recovering spermatogenesis; it builds on earlier work to generate a short list of transcripts as candidate estrogen targets that may control spermatogonial fate, and it provides evidence that these span mRNAs, mi-RNAs, and may possibly involve long-noncoding RNAs [5] .
The Approach
In the established adult irradiated rat testis model for spermatogenic depletion, 6Gy of gamma radiation to the lower body results in testes that contain only undifferentiated spermatogonia [19] . These germ cells do not differentiate and repopulate the testis, rather they undergo apoptosis; based on transplantation experiments, it was concluded that the somatic cell compartment can no longer support germ cell differentiation [20] . However, systemic administration of a gonadotropin releasing hormone (GnRH) agonist or antagonist, low-dose testosterone (T), an androgen antagonist such as flutamide, or estradiol (E2) can drive recovery. Within two weeks after treatment with a GnRH antagonist and flutamide, spermatogonial numbers are elevated 2-fold. Supplemental E2 causes a further spermatogonial doubling. Transcript profiling reported in this manuscript was generated using published [21] and new Affymetrix microarray analyses of testes from irradiated animals treated with a GnRH antagonist (acyline) plus either testosterone, flutamide, flutamide plus FSH, or estradiol, with the last comprising the new dataset. Acyline exposure minimizes the levels of gonadotropins as well as T, while flutamide blocks T actions. Thus, this mix of agents, when combined with E2, produces a testis permissive for spermatogonial differentiation without the influence of T, follicle stimulating hormone or leutinizing hormone. Targets of these latter hormones were identified previously by this group; these were considered during assembly of the list of candidate estrogen targets that could mediate the recovery of sperm formation in the adult testis. An important strategy for simplification of the data analysis was the choice of a time point at 2 weeks post-recovery onset, when the germ cell complement in the testis was not significantly different between untreated controls and the various treatment groups.
The Outcomes
The microarray analyses identified remarkable differences between transcriptional targets identified as up-and downregulated by estrogen. Of the 439 distinct targets identified in the estrogen up-regulated group, 86% were tagged as named genes in GenBank. In contrast, there were nearly 3-fold more down-regulated targets (1155), with only 46% identified as genes. This difference was further exaggerated in the gene cohort with the greatest transcript level change. Amongst the genes down-regulated by estrogen were Leydig cell-expressed Insl3 and Ces, which are also known to be down-regulated by ITT suppression; validation of these by real-time PCR identifies these as potential key mediators of spermatogenic suppression. The possibility that both germ cell and Sertoli cell transcripts are affected is suggested by pre-existing data and is discussed by the authors.
The high proportion of sequences down-regulated by E2 that did not correspond to known genes were shown to include miRNAs and pre-miRNAs, and this information was used to identify a list of their potential mRNA targets. One of these, miR-34a, has been identified as a tumor suppressor gene with affects on cell survival and growth [22] , positioning it as likely to control spermatogonial fate. Intriguingly, the frequency of estrogen receptor binding elements did not differ between the promoters of candidate estrogen targets and unregulated genes, suggesting that only a subset are regulated by estrogen directly. There was also no enrichment for E2-regulated transcription factor binding sites found in the target gene promoters nor was enhanced expression of such transcription factors found. The potential for long, noncoding RNAs to constitute a significant component of the estrogen targets has been only briefly addressed as being important for further consideration.
The Potential
After nearly forty years since the first reports of the effects of 17b-estradiol on seminiferous tubules and spermatogenesis and of 17b-estradiol production by Sertoli cells, detailed molecular understanding of how this steroid acts on the testis is emerging [23] [24] [25] [26] . This study provides an example of the sophisticated in vivo models that can be employed to unveil the critical elements that control spermatogenesis within the complex mix of hormones and growth factors in the testis. The transcriptional screening approach provides an intriguing suite of candidate molecular switches that may control spermatogonial fate. Further steps to define the relative importance and roles of these transcripts will reveal which cells produce them, helping to pinpoint the cells that directly contribute to the spermatogonial stem cell niche. Comparison of these molecules and pathways across species may illuminate similarities and differences in spermatogenic recovery potential between animal models and humans. There is no doubt that integration of results provided here with other ongoing work addressing spermatogonial stem cell biology will illuminate the dynamic molecular dialogue that ensures full fertility in males.
